CTRI/2017/03/007996Other未知
Efficacy and safety of SPILs Rifaximin tablets, 200 mg Rifaximin in subjects with travelers diarrhea : A Randomized, Double blind, Parallel group, Active and Placebo Controlled, Clinical Endpoint Bio equivalence Study
Trial Snapshot
- Phase
- 未知
- Status
- Other
- Enrollment
- 1
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1.Willing to participate and give written informed consent.
- •2.Able and willing to comply with the protocol, including availability for all scheduled clinic visits.
- •3.woman of child bearing potential - having a negative urine pregnancy test prior to beginning the therapy and ready to use effective contraceptive methods during the study.
- •4.Experiencing at least three unformed stools recorded within the 24 hours
Exclusion Criteria
- •1.Pregnant, breast feeding or planning a pregnancy.
- •2.Having active, uncontrolled, or clinically significant diseases
- •3.Use of any drug such as aspirin or ibuprofen, which can cause GI bleeding
Investigators
Similar Trials
Recruiting
Not Applicable
Efficacy and safety of Rifaximin for the treatment of liver cirrhosis with covert hepatic encephalopathyiver cirrhosisJPRN-UMIN000044657Wakayama Medical University40
Completed
Phase 2
Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)Overt Hepatic EncephalopathyNCT03515044Bausch Health Americas, Inc.71
Active, not recruiting
Phase 1
Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in Patients with Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath TestModerate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath TestMedDRA version: 20.0Level: PTClassification code 10076537Term: Papulopustular rosaceaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2017-003722-33-ITALFASIGMA S.P.A.236
Active, not recruiting
Phase 1
Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in Patients with Moderate-to-Severe Papulopustular RosaceaEUCTR2017-003722-33-DEALFASIGMA S.P.A.228
Not yet recruiting
Unknown
The effect of Rifaximin (an antibiotic drug commonly used in liver failure patients) and standard medical therapy vs standard medical therapy alone on myosteatosis (fat deposition in abdominal muscles), in patients with decompensated cirrhosis- a randomized controlled trialCTRI/2024/07/069984PGIMER, CHANDIGARH